安徽丰原药业股份有限公司 董事会审计委员会实施细则（修订案） （经 2024 年 4 月 24 日公司第九届十七次董事会审议通过） 第一章 总 则 第一条 为强化安徽丰原药业股份有限公司（下称"公司"）董事会决策功能， 确保董事会对经理层的有效监督，完善公司治理结构，根据《中华人民共和国公司 法》、《上市公司治理准则》、《深圳证券交易所上市公司自律监管指引第 1 号— 主板上市公司规范运作》、《公司章程》及其他有关规定，公司特设立董事会审计 委员会（下称"审计委员会"），并制定本实施细则。 第二条 董事会审计委员会是董事会按照股东大会决议设立的专门工作机构， 主要负责公司内、外部审计的沟通、监督和核查工作。 第二章 人员组成 第三条 审计委员会成员由三名董事组成，独立董事占多数，委员中至少有一 名独立董事为专业会计人士。审计委员会成员应当为不在公司担任高级管理人员的 董事。 第四条 审计委员会委员由董事长、二分之一以上独立董事或者全体董事的三 分之一提名，并由董事会选举产生。 第五条 审计委员会设主任委员（召集人）一名，由作为专业会计人士的独立 董事委员担任，负责主持审计委员会工作；主任委员在委员内独立董事中 ...

安徽丰原药业股份有限公司 独立董事专门会议工作制度 （经 2024 年 4 月 24 日公司第九届十七次董事会审议通过） （二）公司及相关方变更或者豁免承诺的方案； （三）被收购公司董事会针对收购所作出的决策及采取的措施； （四）法律、行政法规、中国证监会规定、深交所业务规则和《公司章程》 规定的其他事项。 第一章 总则 第一条 为进一步完善安徽丰原药业股份有限公司（下称"公司"）治理结 构，充分发挥独立董事在董事会中参与决策、监督制衡、专业咨询等职能，维护 公司整体利益，保护中小股东合法权益，根据《上市公司独立董事管理办法》《深 圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号 ——主板上市公司规范运作》以及《公司章程》等有关规定，并结合公司实际情 况，制定本工作制度。 第二条 独立董事专门会议（下称"专门会议"）是指全部由公司独立董事 参加的会议。关联交易等潜在重大利益冲突事项在提交董事会审议前，应当由独 立董事专门会议进行事前认可。 独立董事是指不在公司担任除董事外的其他职务，并与公司及其主要股东、 实际控制人不存在直接或者间接利害关系，或者其他可能影响其进行独立客观判 断关系的 ...

关于安徽丰原药业股份有限公司 2023 年度 非经营性资金占用及其他关联资金往来情况的专项说明 中证天通会计师事务所（特殊普通合伙） 中国·北京 中证天通 关于安徽丰原药业股份有限公司 2023 年度 非经营性资金占用及其他关联资金往来情况的专项说明 中证天通 附表：安徽丰原药业股份有限公司 2023 年度非经营性资金占用及其 他关联资金往来情况汇总表 中证天通（2024）证审字 21120029-1 号 安徽丰原药业股份有限公司全体股东： 我们接受委托，审计了安徽丰原药业股份有限公司（以下简称"丰原 药业"）财务报表，包括 2023 年 12 月 31 日的合并及公司资产负债表， 2023 年度的合并及公司利润表、合并及公司现金流量表、合并及公司股 东权益变动表以及财务报表附注（以下简称"财务报表"），并于 2024 年 4 月 24 日出具了标准无保留意见的审计报告（审计报告编号：中证天 通（2024）证审字 2112-0029-1 号）。 根据《上市公司监管指引第 8 号——上市公司资金往来、对外担保的 监管要求》（中国证券监督管理委员会公告〔2022〕26 号）的要求，丰 原药业编制了本专项说明所附的 ...

证券代码：000153 证券简称：丰原药业 公告编号：2024-015 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 安徽丰原药业股份有限公司（下称"公司"）于 2024 年 4 月 24 日召开第九届董 事会第十七次会议，审议通过《关于续聘会计师事务所及其报酬的议案》，公司拟续 聘中证天通会计师事务所（特殊普通合伙）（以下简称"中证天通"）为公司 2024 年 度财务审计机构。具体情况如下： 一、关于续聘公司 2024 年度审计机构的情况说明 中证天通具备从事证券、期货相关业务资格，具有丰富的审计工作经验，在过 去的审计服务中，中证天通严格遵循相关法律、法规和政策，遵照独立、客观、公 正的执业准侧，勤勉尽责，较好地完成了公司各项审计工作，其出具的各项报告能 够客观、公正、公允地反映公司财务情况和经营结果，切实履行了审计机构职责， 从专业角度维护了公司及股东的合法权益。为保持审计工作的连续性，公司拟续聘 中证天通为公司 2024 年度财务审计及内控鉴证机构，公司拟支付其 2024 年度财务 审计和内控审计报酬分别为 95 万元和 30 万元，并承担会计师事务 ...

Financial Performance - The company's revenue for Q1 2024 was CNY 1,120,669,012.93, a decrease of 7.08% compared to CNY 1,206,114,496.19 in the same period last year[4] - Net profit attributable to shareholders was CNY 47,010,852.21, reflecting a 2.14% increase from CNY 46,024,429.74 year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 41,674,569.58, up 4.96% from CNY 39,706,065.28 in the previous year[4] - Total operating revenue for Q1 2024 was CNY 1,120,669,012.93, a decrease of 7.1% from CNY 1,206,114,496.19 in the same period last year[16] - Net profit for Q1 2024 was CNY 46,363,541.16, reflecting a 1.6% increase from CNY 45,642,875.16 in the previous year[17] - Earnings per share (EPS) for Q1 2024 was CNY 0.1416, up from CNY 0.1386 in Q1 2023, indicating a growth of 2.2%[18] Cash Flow - The net cash flow from operating activities decreased by 21.29% to CNY 15,777,633.43 from CNY 20,045,680.47 in the same period last year[4] - Cash flow from operating activities totaled CNY 977,470,684.37, a decrease of 5.5% compared to CNY 1,034,532,225.52 in the same quarter last year[19] - The net cash flow from operating activities was 15,777,633.43 CNY, a decrease of 21.2% compared to 20,045,680.47 CNY in the previous year[21] - The total cash outflow from investing activities was 114,711,320.33 CNY, significantly higher than 28,798,232.70 CNY in the same period last year[21] - The net cash flow from financing activities was 81,911,173.50 CNY, a recovery from a negative cash flow of -138,883,346.02 CNY in the previous year[21] - The total cash and cash equivalents at the end of the period were 273,739,417.10 CNY, down from 344,672,700.29 CNY at the beginning of the period[21] Assets and Liabilities - Total assets increased by 7.10% to CNY 4,703,099,357.93 compared to CNY 4,391,320,148.20 at the end of the previous year[4] - Total current assets increased to ¥2,124,341,394.28 from ¥1,902,911,251.25, reflecting a growth of approximately 11.65%[13] - Total liabilities increased to CNY 2,732,348,255.43, up from CNY 2,472,494,405.67, representing an increase of 10.5%[17] - Current liabilities increased to ¥2,252,977,334.26 from ¥2,013,636,055.35, reflecting a rise of about 11.85%[14] - Short-term borrowings increased to ¥433,731,902.78 from ¥344,286,277.78, an increase of approximately 26.1%[14] Shareholder Information - Total number of common shareholders at the end of the reporting period is 40,268[10] - The largest shareholder, Anhui Wuwei Pharmaceutical Factory, holds 10.79% of shares, totaling 35,842,137 shares[10] - Shareholders' equity attributable to the parent company rose by 2.67% to CNY 1,939,900,305.48 from CNY 1,889,409,585.59 at the end of last year[4] - Total equity attributable to shareholders of the parent company rose to CNY 1,939,900,305.48, compared to CNY 1,889,409,585.59, an increase of 2.7%[17] Research and Development - Research and development expenses decreased by 48.14% to CNY 12,983,646.70 from CNY 25,035,890.83 in the previous year[8] - Research and development expenses were CNY 12,983,646.70, significantly reduced from CNY 25,035,890.83 in Q1 2023, marking a decrease of 48.2%[17] Other Income and Expenses - The company reported a significant increase of 153.81% in other income, totaling CNY 18,765,531.63, primarily due to increased government subsidies[8] - Total operating costs decreased to CNY 1,058,729,460.12, down 7.6% from CNY 1,145,309,254.54 year-on-year[16] - The company reported a decrease in sales expenses to CNY 159,552,828.87, down 20.4% from CNY 200,444,348.75 in the previous year[17] Inventory and Receivables - Accounts receivable rose to ¥1,025,692,442.00 from ¥791,523,059.81, an increase of about 29.5%[13] - Inventory decreased slightly to ¥569,163,882.62 from ¥573,578,704.53, a decline of about 0.77%[13] Audit Status - The company has not yet audited the first quarter report for 2024[22]

安徽丰原药业股份有限公司 独立董事 2023 年度述职报告 作为安徽丰原药业股份有限公司（以下简称"公司"）的独立董事， 2023年度， 本人严格按照《中华人民共和国公司法》、《关于在上市公司建立独立董事的指导意 见》等法律、法规及《公司章程》的有关规定，以维护公司和广大投资者的利益为宗 旨，积极参与公司董事会的决策事项，并对重大事项发表独立意见，充分发挥了独立 董事应有的作用。 一、出席会议情况 （一）参加董事会和股东大会情况 1、参加公司 2022 年年度股东大会，并根据会议安排向本次股东大会作独立董事 2022 年度述职报告。 2、按时参加 2023 年度公司董事会召开的历次会议，认真审议历次会议的各项议 案，审慎决策并行使投票权，客观公正地发表独立意见，履行了独立董事勤勉、尽职 的义务。 本人认为，公司董事会、股东大会的召集与召开符合法定程序，重大经营决策事 项均履行了相关决策程序。我们对公司董事会所审议的各项议案在认真审阅的基础上 均表示同意，无提出反对、弃权意见的情形。 3、2023 年度本人参加董事会、股东大会情况。 | 独立董事 | 应参加 | 现场出席 | 以通讯方式 | 委托出席次数 | ...

安徽丰原药业股份有限公司 中证天通会计师事务所 （特殊普通合伙） 中国·北京 海淀区西直门北大街 43 号 金运大厦 B 座 13 层 邮编 100044 电话 010 6221 2990 传真 010 6225 4941 网址 www.zzttcpa.com 审计报告 中证天通（2024）证审字 21120029 号 2023 年度 财务报表之审计报告 目 录 | 一、审计报告 | 1-6 | | --- | --- | | 二、已审公司财务报表 | | | 1.合并资产负债表 | 1-2 | | 2.母公司资产负债表 | 3-4 | | 3.合并及公司利润表 | 5 | | 4.母公司利润表 | 6 | | 5.合并现金流量表 | 7 | | 6.母公司现金流量表 | 8 | | 7.合并所有者（股东）权益变动表 | 9-10 | | 8.母公司所有者（股东）权益变动表 | 11-12 | | 9.财务报表附注 | 13-102 | 中证天通会计师事务所（特殊普通合伙） 关键审计事项是我们根据职业判断，认为对本期财务报表审计最为重要 的事项。这些事项的应对以对财务报表整体进行审计并形成审计意见为背 景，我 ...

股票简称：丰原药业 股票代码：000153 公告编号：2024-019 安徽丰原药业股份有限公司关于 召开 2023 年度股东大会的通知 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈述或 者重大遗漏。 安徽丰原药业股份有限公司（下称"公司"）定于 2024 年 5 月 22 日召开 2023 年 度股东大会，现将有关事项通知如下： 一、召开会议基本情况 （一）股东大会届次：公司 2023 年度股东大会。 （二）会议召集人：公司第九届董事会。公司第九届十七次董事会审议通过， 决定召开公司 2023 年度股东大会。 （三）会议召开的合法、合规性：本次股东大会会议召集、召开程序符合《公 司法》等法律、法规及《公司章程》的相关规定。 （四）召开的日期、时间： 1、现场会议召开时间：2024 年 5 月 22 日下午 14:30 2、网络投票时间： 通过深圳证券交易所交易系统进行网络投票的时间为：2024 年 5 月 22 日上午 9:15－9:25、9:30－11:30，下午 13:00－15:00；通过深圳证券交易所互联网投票系统 （http://wltp.cninfo.com.cn ...

股票简称：丰原药业 股票代码：000153 公告编号：2024-020 安徽丰原药业股份有限公司 关于修订《公司章程》《股东大会议事规则》 及《董事会议事规则》的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性陈 述或者重大遗漏。 安徽丰原药业股份有限公司（下称"公司"或"本公司"），根据中国证监会 《上市公司章程指引》《上市公司独立董事管理办法》《上市公司监管指引第 3 号 ——上市公司现金分红》及《深圳证券交易所股票上市规则》《深圳证券交易所 上市公司自律监管指引第 1 号——主板上市公司规范运作》等规范性文件的相 关规定，并结合公司实际情况，拟对《公司章程》及《股东大会议事规则》《董 事会议事规则》进行修订。现将有关情况公告如下： | 原条款 | 修订后的条款 | | --- | --- | | 第二十九条 公司董事、监事、高级管理人员、 | 第二十九条 公司持有 5%以上股份的股东、 | | 持有本公司股份 5%以上的股东，将其持有的本公 | 董事、监事、高级管理人员，将其持有的本公司 | | 司股票在买入后 6 个月内卖出，或者在卖出后 6 | 股票或者其他具有股权性 ...

Financial Performance - The company's operating revenue for 2023 reached ¥4,275,436,713.72, representing a 6.78% increase compared to ¥4,004,020,381.58 in 2022[22]. - The net profit attributable to shareholders for 2023 was ¥159,285,567.90, reflecting a 3.15% increase from ¥154,426,589.40 in the previous year[22]. - The net profit after deducting non-recurring gains and losses increased by 41.12% to ¥128,076,451.66 from ¥90,757,391.98 in 2022[22]. - The basic earnings per share for 2023 was ¥0.4796, a decrease of 1.50% from ¥0.4869 in 2022[22]. - The total assets at the end of 2023 were ¥4,391,320,148.20, down 1.74% from ¥4,469,239,892.87 at the end of 2022[22]. - The net assets attributable to shareholders increased by 9.31% to ¥1,889,409,585.59 from ¥1,728,488,218.94 in 2022[22]. - The total profit reached 21,489.26 million yuan, growing by 6.23% compared to the previous year[42]. - The net profit attributable to shareholders was 15,928.56 million yuan, reflecting a 3.15% increase year-on-year[42]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 12,807.65 million yuan, up by 41.12%[42]. Cash Flow and Investments - The net cash flow from operating activities decreased by 42.10% to ¥254,751,792.54 compared to ¥439,990,375.52 in 2022[22]. - The cash and cash equivalents decreased by ¥53,933,787.82 in 2023, marking a decline of 168.78% compared to the previous year[63]. - The total investment amount for the reporting period was ¥183,657,681.77, representing an increase of 8.89% compared to ¥168,669,624.93 in the same period last year[71]. - The company received government subsidies amounting to ¥39,433,999.70, representing 18.35% of total profit[65]. Revenue Breakdown - Revenue from pharmaceutical manufacturing was ¥2,586,139,453.63, accounting for 60.49% of total revenue, with a year-on-year growth of 14.28%[50]. - Revenue from pharmaceutical retail and distribution decreased by 4.64% to ¥1,590,414,915.88, representing 37.20% of total revenue[50]. - The gross profit margin for pharmaceutical manufacturing was 31.56%, down 4.54% from the previous year, with revenue of ¥2,573,341,939.41 and cost of ¥1,761,190,703.60[51]. - The gross profit margin for chemical synthetic drugs was 32.20%, with revenue of ¥2,201,564,374.64 and cost of ¥1,492,623,767.56, reflecting a year-on-year revenue increase of 20.10%[52]. Research and Development - The company focuses on new drug research and development, holding multiple first and second category new drug varieties and several proprietary intellectual property products[34]. - The number of R&D personnel increased slightly by 0.60% to 167 in 2023 from 166 in 2022[62]. - Total R&D investment rose by 27.59% to ¥103,904,597.37 in 2023 compared to ¥81,436,942.31 in 2022, accounting for 2.43% of operating revenue[63]. - R&D expenses increased by 17.65% to ¥77,023,417.77 in 2023 from ¥65,466,089.63 in 2022[61]. Corporate Governance and Management - The company has established a sound corporate governance structure in compliance with relevant laws and regulations, ensuring accurate and timely information disclosure[89]. - The company maintains operational independence from its controlling shareholders, with a complete and independent supply, production, and sales system[90]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 6.2875 million, with independent directors receiving an annual allowance of CNY 60,000 each[104]. - The company has implemented a performance-based salary system for its senior management, aligning compensation with operational goals[104]. Environmental Compliance - The company has established comprehensive wastewater treatment facilities in compliance with various environmental standards to minimize ecological impact[135]. - The company has implemented measures to ensure that emissions of volatile organic compounds are within the limit of 60 mg/Nm3, with actual emissions recorded at 7.98 mg/Nm3[135]. - The company invested a total of 8.1392 million yuan in environmental protection-related expenses during the reporting period[141]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[142]. Market Strategy and Future Outlook - The company aims to enhance its market value through technology development and channel management, focusing on building a comprehensive pharmaceutical enterprise group[81]. - The company plans to strengthen its marketing capabilities by developing high-margin products and expanding sales channels while monitoring industry policy changes[84]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[99]. - New product launches are expected to contribute an additional 300 million CNY in revenue next year[99]. Shareholder Information - The company reported a total of 5,190,000 shares held by senior management at the end of the reporting period, with 1,297,500 shares exercised during the period[126]. - The total number of common shareholders at the end of the reporting period was 40,199, a slight decrease from 40,268 at the end of the previous month[191]. - The company has committed to not trading or transferring non-circulating shares for 24 months after obtaining listing circulation rights, with a maximum of 5% of total shares sold within 12 months and 10% within 24 months[148]. Risks and Challenges - The company faces risks from the implementation of pharmaceutical policies such as consistency evaluation of generic drugs, centralized procurement, and medical insurance cost control, which may significantly impact the competitive landscape of the pharmaceutical industry[85]. - Environmental risks are increasing due to stricter regulations and rising costs associated with waste management in raw material drug production, prompting the company to enhance its environmental protection measures[85]. - The company has invested in venture capital funds, which may lead to longer investment recovery periods and potential losses due to macroeconomic and market factors[85].